A noteworthy prognostic marker in extensive small cell lung cancer: lymphocyte/C-reactive protein ratio
Abstract
Aims: We aimed to investigate the pre-treatment prognostic significance of lymphocyte/C-Reactive protein ratio (LCR), one of the inflammatory factors, in patients with extensive-stage small cell lung cancer (SCLC).
Methods: Medical records of 514 patients who were diagnosed with extensive-stage SCLC between 2010 and 2020 were examined retrospectively. LCR was calculated using the blood test results prior to chemotherapy.
Results: The mean survival time for extensive-stage SCLC is 6 months (5.3-6.7). A statistically significant difference exists between limited and extensive stages in terms of median overall survival (OS) (p<0.001). The baseline LCR value of the patients was determined as 0.5 (0-311). LCR exerts a statistically significant effect on overall survival (0.025). Every 1 unit increase in LCR reduces death by 1.004 times.
Conclusion: Pre-treatment LCR value can be used as an independent prognostic parameter associated with mean survival in extensive SCLC.
Project Number
-
References
- Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24(28):4539-4544.
- Bernhardt EB, Jalal SI. Small cell lung cancer. Cancer Treat Res. 2016;170:301-322.
- Cerny T, Blair V, Anderson H, Bramwell V, Thatcher N. Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer. 1987;39(2):146-149.
- Greten FR, Grivennikov SI. Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity. 2019;51(1):27-41.
- Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008; 454(7203):436-444.
- Yang R, Chang Q, Meng X, Gao N, Wang W. Prognostic value of systemic immune‑inflammation index in cancer: a meta‑analysis. J Cancer. 2018;9:3295‑3302.
- Qi Q, Zhuang L, Shen Y, et al. A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy. Cancer. 2016;122(14):2158-2167.
- Li S, Yang Z, Du H, Zhang W, Che G, Liu L. Novel systemic inflammation response index to predict prognosis after thoracoscopic lung cancer surgery: a propensity score-matching study. ANZ J Surg. 2019;89(11):E507-E513.
- Öztürk Ergür F, Öztürk A. A new prognostic marker in small cell lung cancer: red cell distribution width ratio of hemoglobin. Anatolian Curr Med J. 2023; 5(2); 148-152.
- Bozkaya Y, Kurt B, Gürler F. A prognostic parameter in advanced non‑small cell lung cancer: the ratio of hemoglobin‑to‑red cell distribution width. Int J Clin Oncol. 2019;24:798‑806.
- He Y, Gong R, Peng KW, Liu LZ, Sun LY, Wang HY. Lymphocyte-to-C-reactive protein ratio is a potential new prognostic biomarker for patients with lung cancer. Biomark Med. 2020;14(9):717-726.
- Yılmaz H, Yersal Ö. Prognostic significance of novel inflammatory markers in extensive-stage small-cell lung cancer. J Can Res Ther. 2022;18:691-696.
- İriağaç Y, Çavdar E, Yolcu A. The prognostic importance of lymphocyte/monocyte ratio in diffuse stage small cell lung cancer. Ahi Evran Med J. 2022; 6 (1):71-76.
- Rami-Porta R, Asamura H, Travis WD, Rusch VW. Lung cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(2):138-155.
Abstract
Amaç: Yaygın evre küçük hücreli akciğer kanseri (KHAK) hastalarında inflamatuar faktörlerden lenfosit/C-Reaktif protein oranının (LCR) tedavi öncesi prognostik önemini araştırmayı amaçladık.
Araçlar ve Yöntem: Retrospektif olarak 2010-2020 tarihleri arasında KHAK tanısı almış ve yaygın evrede olan 514 hastanın tıbbi kayıtları incelendi. Kemoterapi öncesi alınan kan tetkiklerinden LCR hesaplandı.
Bulgular: Yaygın evre KHAK’nin ortalama sağkalım süresi 6 aydır (5,3-6,7). Sınırlı ve yaygın hastalık arasında medyan genel sağkalım (OS) açısından istatistiksel anlamlı farklılık vardır (p<0.001). Hastaların başlangıç LCR değeri 0,5 (0-311) olarak saptandı. LCR’nin genel sağkalım üzerinde istatistiksel anlamlı etkisi vardır (0,025). LCR’deki 1 birimlik artış ölümü 1,004 kat azaltmaktadır
Sonuç: Tedavi öncesi LCR, yaygın evre KHAK’de ortalama sağkalımı gösteren bağımsız bir prognostik parametre olarak kullanılabilir.
Supporting Institution
yok
Project Number
-
Thanks
Sayın editörlerimize saygılarımı sunarım
References
- Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24(28):4539-4544.
- Bernhardt EB, Jalal SI. Small cell lung cancer. Cancer Treat Res. 2016;170:301-322.
- Cerny T, Blair V, Anderson H, Bramwell V, Thatcher N. Pretreatment prognostic factors and scoring system in 407 small-cell lung cancer patients. Int J Cancer. 1987;39(2):146-149.
- Greten FR, Grivennikov SI. Inflammation and Cancer: Triggers, Mechanisms, and Consequences. Immunity. 2019;51(1):27-41.
- Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008; 454(7203):436-444.
- Yang R, Chang Q, Meng X, Gao N, Wang W. Prognostic value of systemic immune‑inflammation index in cancer: a meta‑analysis. J Cancer. 2018;9:3295‑3302.
- Qi Q, Zhuang L, Shen Y, et al. A novel systemic inflammation response index (SIRI) for predicting the survival of patients with pancreatic cancer after chemotherapy. Cancer. 2016;122(14):2158-2167.
- Li S, Yang Z, Du H, Zhang W, Che G, Liu L. Novel systemic inflammation response index to predict prognosis after thoracoscopic lung cancer surgery: a propensity score-matching study. ANZ J Surg. 2019;89(11):E507-E513.
- Öztürk Ergür F, Öztürk A. A new prognostic marker in small cell lung cancer: red cell distribution width ratio of hemoglobin. Anatolian Curr Med J. 2023; 5(2); 148-152.
- Bozkaya Y, Kurt B, Gürler F. A prognostic parameter in advanced non‑small cell lung cancer: the ratio of hemoglobin‑to‑red cell distribution width. Int J Clin Oncol. 2019;24:798‑806.
- He Y, Gong R, Peng KW, Liu LZ, Sun LY, Wang HY. Lymphocyte-to-C-reactive protein ratio is a potential new prognostic biomarker for patients with lung cancer. Biomark Med. 2020;14(9):717-726.
- Yılmaz H, Yersal Ö. Prognostic significance of novel inflammatory markers in extensive-stage small-cell lung cancer. J Can Res Ther. 2022;18:691-696.
- İriağaç Y, Çavdar E, Yolcu A. The prognostic importance of lymphocyte/monocyte ratio in diffuse stage small cell lung cancer. Ahi Evran Med J. 2022; 6 (1):71-76.
- Rami-Porta R, Asamura H, Travis WD, Rusch VW. Lung cancer - major changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(2):138-155.
Details
| Primary Language | English |
|---|---|
| Subjects | Chest Diseases |
| Journal Section | Research Articles [en] Araştırma Makaleleri [tr] |
| Authors | |
| Project Number | - |
| Publication Date | August 30, 2023 |
| Published in Issue | Year 2023 Volume: 4 Issue: 4 |
TR DİZİN ULAKBİM and International Indexes (1d)
Interuniversity Board (UAK) Equivalency: Article published in Ulakbim TR Index journal [10 POINTS], and Article published in other (excuding 1a, b, c) international indexed journal (1d) [5 POINTS]
| ||
|
|
|
|
|
|
|
|
Our journal is in TR-Dizin, DRJI (Directory of Research Journals Indexing, General Impact Factor, Google Scholar, Researchgate, CrossRef (DOI), ROAD, ASOS Index, Turk Medline Index, Eurasian Scientific Journal Index (ESJI), and Turkiye Citation Index.
EBSCO, DOAJ, OAJI and ProQuest Index are in process of evaluation.
Journal articles are evaluated as "Double-Blind Peer Review".